NCT00534430
Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 23 versions: 21 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial status: Active, Not Recruiting to Completed
- Study completion date changed from estimate of Mar 18, 2026 to Feb 2, 2026
- Minor Study completion date: Apr 9, 2025 to Mar 18, 2026v22
- Minor Study completion date: Dec 30, 2024 to Apr 9, 2025v21
- Minor Study completion date: Dec 30, 2023 to Dec 30, 2024v20
Notable Results first posted: Oct 10, 2023v19 Show 5 more changesShow less
- Primary endpoints: 3 to 4
- Enrollment target: estimated 50 to confirmed 30
- Primary completion date changed from estimate of Dec 30, 2022 to Apr 12, 2010
- Study completion date: Dec 30, 2022 to Dec 30, 2023
- Secondary endpoints shortened, about 4 words
Show 15 earlier versionsHide 15 earlier versions
- Notable Primary and study completion dates: Dec 30, 2021 to Dec 30, 2022v18
- Notable Primary and study completion dates: Aug 2019 to Dec 30, 2021
- Start date: Jan 2000 to Feb 29, 2000
- Notable Primary and study completion dates: Sep 2018 to Aug 2019v16
- Notable Primary and study completion dates: Jan 2018 to Sep 2018v15
- Notable Primary completion date: Jan 2017 to Jan 2018
- Study completion date: Jan 2018
- Notable Primary completion date: Jun 2016 to Jan 2017v13
- Notable Primary completion date: Jun 2014 to Jun 2016
- Primary endpoints revised (3)
- Secondary endpoints: details revised at 1 of 1 entry
- Study arms: 0 to 1
- Notable Primary completion date: Jun 2013 to Jun 2014v11
- Notable Primary completion date: Oct 2012 to Jun 2013v10
- Minor Primary completion date: Oct 2012v9
- Notable Lead sponsor: Beckman Research Institute to City of Hope Medical Centerv8
- Minor Interventions: allogeneic bone marrow transplantation (Procedure), allogeneic hematopoietic stem cell transplantation (Procedure), busulfan (Drug)… to allogeneic bone marrow transplantation (Procedure), allogeneic hematopoietic stem cell transplantation (Procedure), busulfan (Drug)…v7
- Minor Interventions: allogeneic bone marrow transplantation (Procedure), allogeneic hematopoietic stem cell transplantation (Procedure), busulfan (Drug)… to allogeneic bone marrow transplantation (Procedure), allogeneic hematopoietic stem cell transplantation (Procedure), busulfan (Drug)…v5
- Minor Interventions: allogeneic bone marrow transplantation (Procedure), allogeneic hematopoietic stem cell transplantation (Procedure), biological therapy… to allogeneic bone marrow transplantation (Procedure), allogeneic hematopoietic stem cell transplantation (Procedure), busulfan (Drug)…v3
- Minor Study description shortened, about 2 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Overall Survival at 5 Years Post-Transplant.
Timeframe: Date of Transplant to Five Years post-Transplant
Disease-free Survival at Five Years Post-transplant
Timeframe: Date of transplant to five years post-transplant
Overall Survival Comparing Diagnosis Groups
Timeframe: Date of Transplant to Five Years post-Transplant
Cumulative Incidence of Relapse With Transplant-related Death as the Competing Risk: Diagnosis Groups Are Compared.
Timeframe: Date of Transplant to Five Years post-Transplant. Estimate is at Five Years post-Transplant.
Arms and interventions
Busulfan, FTBI and VP16Experimental
IV Busulfan + 12 cGy FTBI + VP16 prior to allogeneic Bone Marrow Transplant
Drugs: busulfan, cyclosporine, etoposide, mycophenolate mofetil
Procedures: allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Radiation: total-body irradiation